Group 1 - In the first 11 months of the year, 626 out of 650 comparable QDII funds saw an increase in net value, representing 96.3% of the total [1] - The innovative pharmaceutical sector has rebounded, leading to significant gains for funds heavily invested in this area, with the top-performing fund, Huatai Fuhong Hong Kong Advantage Selection Mixed A/C, achieving a return of 141.57% [1] - The fund's investment strategy focuses on innovative drugs with global competitiveness and high barriers in the medical equipment sector [1] Group 2 - Nine QDII funds recorded gains exceeding 87% in the first 11 months, with four funds from E Fund Management achieving over 92% returns [2] - The top holdings of these funds include companies like Fuhong Hanlin, Xinda Biopharmaceutical, and Keren Biotech [2] - Other high-performing funds include Chuangjin Hexin Global Pharmaceutical Biotechnology Stock Initiation A and C, and GF CSI Hong Kong Innovative Medicine ETF, with returns of 100.32% and 99.68% respectively [2] Group 3 - The Industrial Bank New Economy Mixed Dollar fund, managed by Zhao Bei, has top holdings including Xinda Biopharmaceutical and Jinfang Pharmaceutical [3] - Funds focused on oil and gas, as well as real estate, have underperformed, particularly those tracking the FTSE Saudi Arabia Index [3] Group 4 - The top 10 QDII funds by performance in the first 11 months include Huatai Fuhong Hong Kong Advantage Selection Mixed A, with a return of 141.57%, and E Fund Global Pharmaceutical Industry Mixed C, with a return of 95.67% [4] - The performance of these funds highlights the strong returns in the pharmaceutical sector compared to other sectors like oil and real estate [4]

Core Viewpoint - The Energy ETF Guangfa (159945) opened at a decline of 0.34%, indicating a slight downturn in the energy sector on December 5th [1] Group 1: ETF Performance - The Energy ETF Guangfa (159945) opened at 1.187 yuan [1] - Since its establishment on June 25, 2015, the fund has achieved a return of 19.05% [1] - The fund's performance over the past month has seen a decline of 0.68% [1] Group 2: Major Holdings - Major stocks within the Energy ETF include: - China Shenhua: down 0.36% - China Petroleum: down 0.30% - Shaanxi Coal and Chemical Industry: up 0.44% - China Petroleum & Chemical Corporation: unchanged - China National Offshore Oil Corporation: up 0.21% - Jereh Oilfield Services: up 0.46% - Yanzhou Coal Mining: down 0.14% - Guanghui Energy: unchanged - China Coal Energy: down 0.36% - Shanxi Coking Coal: up 0.30% [1]

Core Insights - The Hong Kong Innovative Drug ETF (513120) increased by 1.99% on December 4, with a trading volume of 4.785 billion yuan [1] - The fund's shares rose by 23 million to a total of 1.8832 billion shares, with an increase of 541 million shares over the past 20 trading days [1] - The latest net asset value of the fund is 25.204 billion yuan [1] - The fund's performance benchmark is the return of the CSI Hong Kong Innovative Drug Index (in RMB), managed by Guangfa Fund Management Co., Ltd. [1] - Since its inception on July 1, 2022, the fund has achieved a return of 33.83%, with a return of 0.35% over the past month [1]

Core Viewpoint - The Hong Kong Stock Connect Non-Bank ETF (513750) experienced a decline of 2.05% with a trading volume of 734 million yuan, indicating a decrease in investor interest [1] Group 1: Fund Performance - The fund's latest net asset value is calculated at 24.388 billion yuan [1] - Since its inception on November 10, 2023, the fund has achieved a return of 62.93% [1] - Over the past month, the fund has recorded a return of -3.13% [1] Group 2: Fund Management - The fund is managed by GF Fund Management Co., Ltd. [1] - The fund managers are Luo Guoqing and Cao Shiyu [1] Group 3: Fund Size and Activity - The fund's shares decreased by 14 million to a total of 14.965 billion shares [1] - In the last 20 trading days, the fund's shares increased by 1.23 billion [1]

Group 1 - The core point of the news is the announcement of the departure of Tang Xiaobin from the position of fund manager for the Guangfa Ruijin One-Year Open Mixed Fund [1] - Tang Xiaobin has a background as a researcher at Huatai United Securities and has held various positions at Guangfa Fund Management, including industry researcher and investment manager [1] - The Guangfa Ruijin One-Year Open Mixed Fund was established on September 15, 2021, and as of December 2, 2025, it has a year-to-date return of 17.49% and a cumulative return of -27.79%, with a net asset value of 0.7221 yuan [1][2] Group 2 - The fund is managed by Guangfa Fund Management Co., Ltd., and the announcement is based on regulatory guidelines for public offering securities investment funds [2] - The fund manager change is classified as the dismissal of the fund manager, with other co-managers being Ye Shuai and Zeng Zhibin [2]

公告称，广发中证全指食品交易型开放式指数证券投资基金(基金代码：563850；认购代码：563853； 场内简称：食品广发；扩位简称：食品ETF广发；以下简称本基金)于2025年11月3日获中国证监会准予 募集注册(证监许可〔2025〕2439号)。 该基金原定募集期为2025年11月24日至2025年12月2日。现决定将该基金的募集日期变更为2025年11月 24日至2025年12月5日。 该基金拟任基金经理姚曦，自2021年11月17日起任职基金经理。 中国经济网北京12月3日讯今日，广发基金管理有限公司发布关于调整广发中证全指食品交易型开放式 指数证券投资基金募集期的公告。 ...

能源ETF广发（159945）业绩比较基准为中证全指能源指数，管理人为广发基金管理有限公司，基金经 理为姚曦，成立（2015-06-25）以来回报为18.77%，近一个月回报为1.77%。 来源：新浪基金∞工作室 12月3日，截止午间收盘，能源ETF广发（159945）涨0.59%，报1.196元，成交额63.41万元。能源ETF 广发（159945）重仓股方面，中国神华截止午盘涨0.50%，中国石油跌0.30%，陕西煤业跌0.39%，中国 石化跌0.33%，中国海油涨0.21%，杰瑞股份涨10.00%，兖矿能源涨1.36%，广汇能源跌0.20%，中煤能 源涨2.43%，山西焦煤涨0.15%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 ...

1. Report Industry Investment Rating No information provided in the content. 2. Core View of the Report - Yang Dong's team combines subjective research with quantitative investment to build a product matrix with high strategic uniqueness and wide coverage, offering diverse investment solutions [102][103]. - The team's products can be divided into two categories: bottom - position funds aiming to outperform mainstream indices and style - enhancing funds for more advanced investors [102]. - The team has two unique features: providing a diversified product matrix with low - correlation strategies and obtaining excess returns from the comprehensive support of the team and platform [103][104]. 3. Summary According to Relevant Catalogs 3.1广发基金杨冬：主观研究与量化投资相结合，构建策略独特性高、覆盖度广的产品矩阵 - **Fund Manager Introduction**: Yang Dong, with 19 years of securities experience and 16 years of investment management experience, uses a combination of "subjective long - only + quantitative investment" framework, integrating macro - judgment and individual - stock Alpha capture [8][9]. - **Managed Products**: Yang Dong manages 8 public funds with a total scale of 25.065 billion yuan. The products are divided into subjective long - only products and "subjective + quantitative" products, each with different investment scopes and characteristics [10]. - **Unique Product Line**: The products meet two major public financial needs. They can be classified into bottom - position funds and style - enhancing funds, with different investment strategies and low correlation [13][19]. 3.2主观多头类产品: 底仓之选,兼顾均衡+价值+成长风格 - **广发多因子**: An equilibrium - style fund that has outperformed three major indices for 8 consecutive years. It has low tracking error and high excess return, with balanced industry style and moderate rotation, and strong stock - selection ability [21][28][32]. - **广发价值领航**: A product with value - growth attributes, featuring moderate valuation and high performance elasticity in the value - type funds. It focuses on PB - ROE strategy, emphasizes growth - elastic non - consumption sectors, and has strong stock - selection ability in the A + H market [45][49][52]. - **广发均衡成长**: An actively - selected product that focuses on growth with balanced allocation. It has a high rolling win - rate, strong ability to reach new highs, low - valuation characteristics in growth funds, and can capture industry and individual - stock opportunities [60][61][68]. 3.3 "主观+量化" 类产品: 风格增强, 差异化 Smart Beta+聚焦板块 - **广发稳健策略**: A dividend - style enhanced product that balances high dividends and growth speed, with prominent excess returns and the ability to control drawdowns. It actively allocates Hong Kong stocks and creates a differentiated dividend portfolio [78][81][87]. - **广发成长智选**: Positioned as a growth - style enhanced product, it focuses on high - growth sectors, has strong industry - rotation ability, and constructs a portfolio by selecting undervalued growth - elastic stocks [89][92]. - **广发智选系列**: The "Smart Selection" series of products, including manufacturing, technology, and resource selection funds, uses a composite strategy of "subjective long - only + active quantification + AI enhancement" to pursue significant excess returns. They have high concentration in certain industries and a "quantitative - led + active - enhanced" stock - selection feature [94][97][100]. 3.4 Summary - The public funds managed by Yang Dong's team meet two major investment needs: long - term bottom - position products and style - distinct allocation products [102]. - The team's unique features lie in providing a diverse product matrix with low - correlation strategies and obtaining excess returns from the comprehensive support of the team and platform, which meets the requirements of the industry's development trend and relevant policies [103][105].

Group 1: Report Industry Investment Rating - No relevant content provided Group 2: Core Views of the Report - Yang Dong's fundamental quantitative team provides a product matrix with diverse strategies and low correlations, and the excess returns come from the comprehensive support of the team and the platform [115][116][117] - Yang Dong's team's products mainly fall into two categories: bottom - position funds aiming to beat mainstream indices and style - enhancing funds for enhanced performance [115] Group 3: Summary According to the Table of Contents 1. Guangfa Fund Yang Dong: Combining Subjective Research and Quantitative Investment to Build a Product Matrix with High Strategy Uniqueness and Wide Coverage - **Fund Manager Introduction**: Yang Dong, with a master's degree in finance, has 19 years of securities experience and 16 years of investment management experience. He has worked at Guangfa Fund since 2006 and currently holds multiple positions. His team uses a framework combining "subjective long - only + quantitative investment" to pursue excess returns [11] - **Managed Product Situation**: Yang Dong manages 8 public funds with a total scale of 25.065 billion yuan. The products can be divided into subjective long - only products and "subjective + quantitative" products, each with different investment scopes, strategies, and characteristics [13] - **Product Line with Different Positions and Unique Strategies**: From the perspective of user needs, the products are divided into bottom - position funds and style - enhancing funds. Most products have "subjective + quantitative" features, with differences in position ratios. The products pursue strategy differentiation, and most have low correlations [17][19][24] 2. Subjective Long - Only Products: The Choice for Bottom - Position, Balancing Equilibrium, Value, and Growth Styles - **Guangfa Multi - Factor**: An equilibrium - style fund that has outperformed three major indices for 8 consecutive years. It has a "close - to - benchmark + outstanding - excess - return" bottom - position fund attribute, with balanced industry style and moderate rotation, and strong stock - selection ability [26][34][45] - **Guangfa Value Pilot**: A product with value - growth attributes and outstanding performance elasticity. It focuses on PB and ROE, has a unique industry structure, and its performance comes from stock - selection and industry contributions, with an emphasis on Hong Kong stocks [53][57][60] - **Guangfa Balanced Growth**: An actively - selected product with high rolling win - rates and many days of reaching new highs within the year. It has low - valuation characteristics among growth funds, with balanced industry allocation and a focus on growth, and the ability to select stocks to contribute excess returns [64][68][79] 3. "Subjective + Quantitative" Products: Style Enhancement, Differentiated Smart Beta + Focus on Sectors - **Guangfa Steady Strategy**: A dividend - style enhanced product that has achieved outstanding absolute and excess returns since Yang Dong took office. It balances income elasticity and drawdown control, combines high dividends and growth, and actively allocates Hong Kong stocks [86][89][96] - **Guangfa Growth Smart Selection**: Positioned as a growth - style enhanced product, it shows relatively stable excess returns compared to the benchmark. It emphasizes high - growth sectors, has the ability to rotate industries, and focuses on A - share growth opportunities [99][102] - **Guangfa Smart Selection Series**: The three "Smart Selection" products use a composite strategy of "subjective long - only + active quantification + AI enhancement". Taking Guangfa Manufacturing Smart Selection and Guangfa Technology Smart Selection as examples, they have high industry concentration, a "quantitative - led + active - enhanced" stock - selection feature, and have achieved excess returns compared to the relevant index [105][109][112] 4. Summary - Yang Dong's team's products meet the two solutions provided by public funds: bottom - position funds and style - enhancing funds. The team provides a diverse product matrix with low correlations, and the excess returns come from the comprehensive support of the team and the platform, which is in line with the requirements of the "Action Plan for Promoting the High - Quality Development of Public Funds" [115][116][118]

Group 1 - The Hong Kong Innovative Drug ETF (513120) experienced a decline of 0.44% on December 1, with a trading volume of 3.824 billion yuan [1] - The fund's shares increased by 4 million, bringing the total shares to 18.690 billion, with a notable increase of 1.290 billion shares over the last 20 trading days [1] - The latest net asset value of the fund is calculated at 25.209 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the China Securities Hong Kong Innovative Drug Index (denominated in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its inception on July 1, 2022, the fund has achieved a return of 34.87%, while the return over the past month is -0.55% [1]